Tuberculosis-advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers

The Lancet Infectious Diseases

Volumn 16, Issue 4, 2016, Pages e34-e46

  Wallis, Robert S ^a,b,f   Maeurer, Markus ^c   Mwaba, Peter ^d   Chakaya, Jeremiah ^e   Rustomjee, Roxana ^g   Migliori, Giovanni Battista ^h   Marais, Ben ⁱ   Schito, Marco ^j   Churchyard, Gavin ^a,k,l   Swaminathan, Soumya ^m   Hoelscher, Michael ^n,o   Zumla, Alimuddin ^d,p,q  

^a AURUM INSTITUTE   (South Africa)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY TEACHING HOSPITAL   (Zambia)

^e KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^f TB/HIV Care Association   (South Africa)

^g SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^h IRCCS   (Italy)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

^j CRITICAL PATH INSTITUTE   (United States)

^k LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^l UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^m NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

ⁿ LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^o German Center for Infection Research   (Germany)

^p UNIVERSITY COLLEGE LONDON   (United Kingdom)

^q UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; BTZ 043; CLOFAZIMINE; CPZEN 45; DELAMANID; DOXYCYCLINE; ETHAMBUTOL; FROPENEM; IMATINIB; LEVOFLOXACIN; MEROPENEM; METFORMIN; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; NEW DRUG; NITROIMIDAZOLE; PBTZ 169; POSIZOLID; PRETOMANID; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; SEQ 9; SQ 641; SUTEZOLID; TBA 354; TBI 166; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER;

ANTIBIOTIC SENSITIVITY; CAUSE OF DEATH; CLINICAL RESEARCH; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ERADICATION; DISEASE MARKER; DRUG TARGETING; HUMAN; LATENT TUBERCULOSIS; LOWEST INCOME GROUP; LUNG INJURY; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; TUBERCULOSIS; DRUG DEVELOPMENT; DRUG EFFECTS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTI-INFECTIVE AGENTS; ANTITUBERCULAR AGENTS; BIOMARKERS; DRUG DISCOVERY; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84962566015     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(16)00070-0     Document Type: Review

References (118)

1. Anderson L, Dean A, Falzon D, et al. Global tuberculosis report 2015 2015, World Health Organization, Geneva. 20th edition.
2. Heinrich N, Dawson R, du Bois J, et al. Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients. J Antimicrob Chemother 2015, 70:1558-1566.
3. Boeree MJ, Hoelscher M. High-dose rifampin, SQ109, and moxifloxacin for treating TB: the PanACEA MAMS-TB trial. Conference on Reteroviruses and Opportunistic Infections; Seattle, WA, USA; Feb 23-26, 2015. Session O-7: abstr 95LB.
4. Dorman SE, Savic RM, Goldberg S, et al. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med 2015, 191:333-343.
5. Dawson R, Diacon AH, Everitt D, et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet 2015, 385:1738-1747.
6. Tang S, Yao L, Hao X, et al. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China. Clin Infect Dis 2015, 60:1361-1367.
7. Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 2014, 371:1577-1587.
8. Merle CS, Fielding K, Sow OB, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 2014, 371:1588-1598.
9. Jindani A, Harrison TS, Nunn AJ, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 2014, 371:1599-1608.
10. Pym AS, Diacon AH, Tang SJ, et al. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J 2015, 47:564-574.
11. Piubello A, Harouna SH, Souleymane MB, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis 2014, 18:1188-1194.
12. Kuaban C, Noeske J, Rieder HL, Ait-Khaled N, Abena Foe JL, Trebucq A High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis 2015, 19:517-524.
13. Kuaban C, Kashongwe Z, Bakayoko A, et al. First results with a 9-month regimen for multidrug-resistant tuberculosis (MDR-TB) in francophone Africa. 46th Union World Conference on Lung Health; Cape Town; Dec 2-6, 2015. Session 41.7.
14. Lee M, Lee J, Carroll M, et al. Linezolid for the treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012, 367:1508-1518.
15. Alffenaar JW, van der Laan T, Simons S, et al. Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480. Antimicrob Agents Chemother 2011, 55:1287-1289.
16. Converse PJ, Lee J, Williams KN, et al. Activity of PNU-100480 and its major metabolite in whole blood and broth culture models of tuberculosis. Am Soc Microbiol 2012, 112. abstr GM-A-2052.
17. Williams KN, Stover CK, Zhu T, et al. Promising anti-tuberculosis activity of the oxazolidinone PNU-100480 relative to linezolid in the murine model. Antimicrob Agents Chemother 2009, 53:1314-1319.
18. Williams KN, Brickner SJ, Stover CK, et al. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Am J Respir Crit Care Med 2009, 180:371-376.
19. Zhu T, Friedrich SO, Diacon A, Wallis RS Population pharmacokinetic/pharmacodynamic analysis of the bactericidal activities of sutezolid (pnu-100480) and its major metabolite against intracellular Mycobacterium tuberculosis in ex vivo whole-blood cultures of patients with pulmonary tuberculosis. Antimicrob Agents Chemother 2014, 58:3306-3311.
20. Wallis RS, Jakubiec W, Kumar V, et al. Pharmacokinetics and whole blood bactericidal activity against Mycobacterium tuberculosis of single ascending doses of PNU-100480 in healthy volunteers. J Infect Dis 2010, 202:745-751.
21. Zhang M, Sala C, Dhar N, et al. In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014, 58:3217-3223.
22. Louie A, Eichas K, Files K, et al. Activities of PNU-100480 (PNU 480) alone, PNU 480 plus its major metabolite PNU-101603 (PNU 1603) and PNU 480 plus PNU 1603 in combination with rifampin (RIF) against Mycobacterium tuberculosis: comparison with linezolid. Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL; Sept 17-20, 2011. A1-1737.
23. Wallis RS, Jakubiec W, Kumar V, et al. Biomarker assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. Antimicrob Agents Chemother 2011, 55:567-574.
24. Wallis RS, Dawson R, Friedrich SO, et al. Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. PLoS One 2014, 9:e94462.
25. Furin JJ, Du Bois J, van Brakel E, et al. Early bactericidal activity of AZD5847 in pulmonary tuberculosis. 46th Union World Conference on Lung Health; Cape Town; Dec 2-6, 2015. Session 41.5.
26. Councils EA-BMR Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report. Tubercle 1980, 61:59-69.
27. Sirgel FA, Warren RM, Bottger EC, Klopper M, Victor TC The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks. PLoS One 2013, 8:e59414.
28. ElMaraachli W, Slater M, Berrada ZL, et al. Predicting differential rifamycin resistance in clinical Mycobacterium tuberculosis isolates by specific rpoB mutations. Int J Tuberc Lung Dis 2015, 19:1222-1226.
29. Davies G, Cerri S, Richeldi L Rifabutin for treating pulmonary tuberculosis. Cochrane Database Syst Rev 2007, 4. CD005159.
30. Noufflard H, Berteaux S Antituberculous activity of compound B-663. Ann Inst Pasteur (Paris) 1958, 95:449-455. (in French).
31. Barry VC, Buggle K, Byrne J, Conalty ML, Winder F Absorption, distribution and retention of the riminocompounds in the experimental animal. Ir J Med Sci 1960, 416:345-352.
32. Karat AB, Jeevaratnam A, Karat S, Rao PS Double-blind controlled clinical trial of clofazimine in reactive phases of lepromatous leprosy. BMJ 1970, 1:198-200.
33. Van Deun A, Salim MA, Das AP, Bastian I, Portaels F Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis 2004, 8:560-567.
34. Van Deun A, Maug AK, Salim MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010, 182:684-692.
35. Tyagi S, Ammerman NC, Li SY, et al. Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis. Proc Natl Acad Sci USA 2015, 112:869-874.
36. Irwin SM, Gruppo V, Brooks E, et al. Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas. Antimicrob Agents Chemother 2014, 58:4026-4034.
37. Esposito S, D'Ambrosio L, Tadolini M, et al. ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. Eur Respir J 2014, 44:811-815.
38. De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J 2013, 41:1386-1392.
39. Chambers HF, Turner J, Schecter GF, Kawamura M, Hopewell PC Imipenem for treatment of tuberculosis in mice and humans. Antimicrob Agents Chemother 2005, 49:2816-2821.
40. Hugonnet JE, Tremblay LW, Boshoff HI, Barry CE, Blanchard JS Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 2009, 323:1215-1218.
41. Hugonnet JE, Blanchard JS Irreversible inhibition of the Mycobacterium tuberculosis β-lactamase by clavulanate. Biochemistry 2007, 46:11998-12004.
42. Anglaret X, Chêne G, Attia A, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Lancet 1999, 353:1463-1468. the Cotrimo-CI Study Group.
43. Walker AS, Ford D, Gilks CF, et al. Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet 2010, 375:1278-1286.
44. Hoffmann CJ, Chaisson RE, Martinson NA Cotrimoxazole prophylaxis and tuberculosis risk among people living with HIV. PLoS One 2014, 9:e83750.
45. Zumla A, Maeurer M, Host-Directed Therapies Network, et al. Towards host-directed therapies for tuberculosis. Nat Rev Drug Discov 2015, 14:511-512.
46. Zumla A, Maeurer M Host-directed therapies for tackling multi-drug resistant tuberculosis: learning from the Pasteur-Bechamp debates. Clin Infect Dis 2015, 61:1432-1438. Host-Directed Therapies Network (HDT-NET) Consortium.
47. Wallis RS, Hafner R Advancing host-directed therapy for tuberculosis. Nat Rev Immunol 2015, 15:255-263.
48. Ralph AP, Kenangalem E, Waramori G, et al. High morbidity during treatment and residual pulmonary disability in pulmonary tuberculosis: under-recognised phenomena. PLoS One 2013, 8:e80302.
49. Willcox PA, Ferguson AD Chronic obstructive airways disease following treated pulmonary tuberculosis. Respir Med 1989, 83:195-198.
50. Hnizdo E, Singh T, Churchyard G Chronic pulmonary function impairment caused by initial and recurrent pulmonary tuberculosis following treatment. Thorax 2000, 55:32-38.
51. Shuldiner J, Leventhal A, Chemtob D, Mor Z Mortality after anti-tuberculosis treatment completion: results of long-term follow-up. Int J Tuberc Lung Dis 2016, 20:43-48.
52. Hoger S, Miller T, Katz D, Beavers S, Lykens K Longevity loss among cured tuberculosis patients and the potential value of prevention. Int J Tuberc Lung Dis 2014, 18:1347-1352.
53. O'Kane CM, Elkington PT, Friedland JS Monocyte-dependent oncostatin M and TNF-alpha synergize to stimulate unopposed matrix metalloproteinase-1/3 secretion from human lung fibroblasts in tuberculosis. Eur J Immunol 2008, 38:1321-1330.
54. Dooley DP, Carpenter JL, Rademacher S Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature. Clin Infect Dis 1997, 25:872-887.
55. Critchley JA, Young F, Orton L, Garner P Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2013, 13:223-237.
56. Wallis RS Corticosteroid effects on sputum culture in pulmonary tuberculosis: a meta-regression analysis. Open Forum Infect Dis 2014, 1:ofu020. ofu020.
57. Kjellsson MC, Via LE, Goh A, et al. Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob Agents Chemother 2012, 56:446-457.
58. Sarathy J, Dartois V, Dick T, Gengenbacher M Reduced drug uptake in phenotypically resistant nutrient-starved nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 2013, 57:1648-1653.
59. Adams KN, Takaki K, Connolly LE, et al. Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell 2011, 145:39-53.
60. Wallis RS, Patil S, Cheon SH, et al. Drug tolerance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1999, 43:2600-2606.
61. Bruns H, Stegelmann F, Fabri M, et al. Abelson tyrosine kinase controls phagosomal acidification required for killing of Mycobacterium tuberculosis in human macrophages. J Immunol 2012, 189:4069-4078.
62. Napier RJ, Rafi W, Cheruvu M, et al. Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis. Cell Host Microbe 2011, 10:475-485.
63. Yogalingam G, Pendergast AM Abl kinases regulate autophagy by promoting the trafficking and function of lysosomal components. J Biol Chem 2008, 283:35941-35953.
64. Napier RJ, Norris BA, Swimm A, et al. Low doses of imatinib induce myelopoiesis and enhance host anti-microbial immunity. PLoS Pathog 2015, 11:e1004770.
65. Gotta V, Bouchet S, Widmer N, et al. Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions. Leuk Res 2014, 38:764-772.
66. Singhal A, Kumar P, Hong GS, et al. Metformin as adjunct anti-tuberculosis therapy. Sci Transl Med 2014, 6:263ra159.
67. Ong CW, Elkington PT, Brilha S, et al. Neutrophil-derived MMP-8 drives AMPK-dependent matrix destruction in human pulmonary tuberculosis. PLoS Pathog 2015, 11:e1004917.
68. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 2014, 73:1020-1026.
69. Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol 2015, 173:1387-1399.
70. Subbian S, Tsenova L, O'Brien P, et al. Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology. Am J Pathol 2011, 179:289-301.
71. Subbian S, Tsenova L, O'Brien P, et al. Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs. PLoS Pathog 2011, 7:e1002262.
72. Koo MS, Manca C, Yang G, et al. Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice. PLoS One 2011, 6:e17091.
73. Wallis RS, Pai M, Menzies D, et al. Biomarkers and diagnostics for tuberculosis: a review of progress and current needs and translation into practice. Lancet 2010, 375:1920-1937.
74. Maertzdorf J, Kaufmann SH, Weiner J Toward a unified biosignature for tuberculosis. Cold Spring Harb Perspect Med 2015, 5:a018531.
75. Ueberberg B, Kohns M, Mayatepek E, Jacobsen M Are microRNAs suitable biomarkers of immunity to tuberculosis?. Mol Cell Pediatr 2014, 1:8.
76. Walzl G, Haks MC, Joosten SA, Kleynhans L, Ronacher K, Ottenhoff TH Clinical immunology and multiplex biomarkers of human tuberculosis. Cold Spring Harb Perspect Med 2014, 5:a018515.
77. Nicol MP, Gnanashanmugam D, Browning R, et al. A blueprint to address research gaps in the development of biomarkers for pediatric tuberculosis. Clin Infect Dis 2015, 61(suppl 3):S164-S172.
78. Kurbatova EV, Cegielski JP, Lienhardt C, et al. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. Lancet Respir Med 2015, 3:201-209.
79. Wallis RS, Peppard T, Hermann D Month 2 culture status and treatment duration as predictors of recurrence in pulmonary tuberculosis: model validation and update. PLoS One 2015, 10:e0125403.
80. Wallis RS, Wang C, Meyer D, Thomas N Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a meta-regression model. PLoS One 2013, 8:e71116.
81. Wallis RS TB relapse risk calculator (accessed Dec 28, 2015). http://www.rswallis.com/Pages/TBrelapsecalculator.aspx.
82. Chau CH, Rixe O, McLeod H, Figg WD Validation of analytic methods for biomarkers used in drug development. Clin Cancer Res 2008, 14:5967-5976.
83. Skoura E, Zumla A, Bomanji J Imaging in tuberculosis. Int J Infect Dis 2015, 32:87-93.
84. Coleman MT, Chen RY, Lee M, et al. PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis. Sci Transl Med 2014, 6:265ra167.
85. Chen RY, Dodd LE, Lee M, et al. PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis. Sci Transl Med 2014, 6:265ra166.
86. Fletcher HA, Tanner R, Wallis RS, et al. Inhibition of mycobacterial growth in vitro is enhanced following primary BCG vaccination but not BCG revaccination of human subjects. Clin Vaccine Immunol 2013, 20:1683-1689.
87. Wallis RS Assessment of whole blood bactericidal activity in the evaluation of new anti-tuberculosis drugs. Antituberculosis chemotherapy 2011, 220-226. Karger, Basel. P.R. Donald, P. van Helden (Eds.).
88. Wallis RS, Vinhas SA, Johnson JL, et al. Whole blood bactericidal activity during treatment of pulmonary tuberculosis. J Infect Dis 2003, 187:270-278.
89. Good CE, Healan AM, Blumer JL, et al. Whole blood mycobactericidal activity (WBA) of bedaquiline (BDQ, TMC207) alone and in combination with rifampin (RIF) or rifabutin (RBT) after oral dosing of healthy volunteers. ICAAC 2012, 52. A-1257.
90. Esterhuyse MM, Weiner J, Caron E, et al. Epigenetics and Proteomics Join Transcriptomics in the Quest for Tuberculosis Biomarkers. MBio 2015, 6:e01187-e01215.
91. Zak DE, Penn-Nicholson A, Scriba TJ, et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet 2016, (in press).
92. UNITAID joins health partners to launch new treatment for drug-resistant TB UNITAID, (accessed Dec 28, 2015). http://www.unitaid.eu/en/statements/1433-unitaid-joins-health-partners-to-launch-new-treatment-for-drug-resistant-tb.
93. Johnson JL, Hadad DJ, Dietze R, et al. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med 2009, 180:558-563.
94. Wang JY, Wang JT, Tsai TH, et al. Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis. Int J Tuberc Lung Dis 2010, 14:65-71.
95. Dorman SE, Johnson JL, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009, 180:273-280.
96. Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009, 373:1183-1189.
97. Rustomjee R, Lienhardt C, Kanyok T, et al. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008, 12:128-138.
98. Burman WJ, Goldberg S, Johnson JL, et al. Moxifloxacin versus ethambutol in the first two months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006, 178:331-338.
99. Manjunatha U, Boshoff HI, Barry CE The mechanism of action of PA-824: novel insights from transcriptional profiling. Commun Integr Biol 2009, 2:215-218.
100. Singh R, Manjunatha U, Boshoff HI, et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 2008, 322:1392-1395.
101. Cegielski JP, Dalton T, Yagui M, et al. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2014, 59:1049-1063.
102. Hicks D How can I miss you when you won't go away? 1969, Epic and Sony Music, Japan International.
103. Gelmanova IY, Ahmad Khan F, Becerra MC, et al. Low rates of recurrence after successful treatment of multidrug-resistant tuberculosis in Tomsk, Russia. Int J Tuberc Lung Dis 2015, 19:399-405.
104. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012, 366:2151-2160.
105. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality for multidrug-resistant tuberculosis. Eur Respir J 2012, 41:1393-1400.
106. Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014, 371:723-732.
107. Cox E, Laessig K FDA approval of bedaquiline-the benefit-risk balance for drug-resistant tuberculosis. N Engl J Med 2014, 371:689-691.
108. Lienhardt C, Weyer K, Falzon D, et al. The use of bedaquiline in the treatment of multi-drug resistant tuberculosis: interim policy guidance 2013, World Health Organization, Geneva.
109. Lienhardt C, Jaramillo E, Falzon D, et al. The use of delamanid in the treatment of multidrug-resistant tuberculosis: interim policy guidance 2014, World Health Organization, Geneva.
110. The Global Fund and Partners: fighting tuberculosis across the globe Friends of the Global Fight Against AIDs, TuberculosisTuberculosis, MalariaMalaria, (accessed Feb 26, 2016). http://theglobalfight.org/wp-content/uploads/TB-Nov15.pdf.
111. Nunn AJ, Rusen ID, Van Deun A, et al. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials 2014, 15:353.
112. Spellberg B, Shlaes D Prioritized current unmet needs for antibacterial therapies. Clin Pharmacol Ther 2014, 96:151-153.
113. Obama B Executive order-combating antibiotic-resistant bacteria (accessed Dec 28, 2015). http://www.whitehouse.gov/the-press-office/2014/09/18/executive-order-combating-antibiotic-resistant-bacteria.
114. Holdren JP, Lander E Report to the President on combating antibiotic resistance. Washington DC (accessed Dec 28, 2015). http://www.whitehouse.gov/sites/default/files/microsites/ostp/PCAST/pcast_carb_report_sept2014.pdf.
115. Upton F 21st century cures act (accessed Dec 28, 2015). https://www.congress.gov/bill/114th-congress/house-bill/6/text.
116. Eichler HG, Baird LG, Barker R, et al. From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients. Clin Pharmacol Ther 2015, 97:234-246.
117. Wallis RS, Peppard T Early biomarkers and regulatory innovation in multidrug-resistant tuberculosis. Clin Infect Dis 2015, 61(suppl 3):S160-S163.
118. Zumla A, Petersen E, Nyirenda T, Chakaya J Tackling the tuberculosis epidemic in sub-Saharan Africa-unique opportunities arising from the second European Developing Countries Clinical Trials Partnership (EDCTP) programme 2015-2024. Int J Infect Dis 2015, 32:46-49.